REFERENCES

1. Gurnari C, Pagliuca S, Visconte V. Deciphering the therapeutic resistance in acute myeloid leukemia. Int J Mol Sci. 2020;21:8505.

2. Liu F, Wang H, Liu J, et al. A favorable inductive remission rate for decitabine combined with chemotherapy as a first course in < 60-year-old acute myeloid leukemia patients with myelodysplasia syndrome features. Cancer Med. 2019;8:5108-15.

3. Sobas MA, Turki AT, Ramiro AV, et al. Outcomes with intensive treatment for acute myeloid leukemia: an analysis of two decades of data from the HARMONY Alliance. Haematologica. 2025;110:1126-40.

4. Abraham A, Varatharajan S, Karathedath S, et al. RNA expression of genes involved in cytarabine metabolism and transport predicts cytarabine response in acute myeloid leukemia. Pharmacogenomics. 2015;16:877-90.

5. Rudd SG, Tsesmetzis N, Sanjiv K, et al. Ribonucleotide reductase inhibitors suppress SAMHD1 ara-CTPase activity enhancing cytarabine efficacy. EMBO Mol Med. 2020;12:e10419.

6. Yamauchi T, Negoro E, Kishi S, et al. Intracellular cytarabine triphosphate production correlates to deoxycytidine kinase/cytosolic 5’-nucleotidase II expression ratio in primary acute myeloid leukemia cells. Biochem Pharmacol. 2009;77:1780-6.

7. Galmarini CM, Thomas X, Graham K, et al. Deoxycytidine kinase and cN-II nucleotidase expression in blast cells predict survival in acute myeloid leukaemia patients treated with cytarabine. Br J Haematol. 2003;122:53-60.

8. Ghiraldeli L, Anderson R, Pladna K, Pardee TS. Adenosine monophosphate activated protein kinase (AMPK) enhances chemotherapy response in acute myeloid leukemia (AML). Cancer Lett. 2022;535:215659.

9. Döhner H, Wei AH, Appelbaum FR, et al. Diagnosis and management of AML in adults: 2022 recommendations from an international expert panel on behalf of the ELN. Blood. 2022;140:1345-77.

10. Ferrell PB Jr, Diggins KE, Polikowsky HG, Mohan SR, Seegmiller AC, Irish JM. High-dimensional analysis of acute myeloid leukemia reveals phenotypic changes in persistent cells during induction therapy. PLoS One. 2016;11:e0153207.

11. Machon C, Jordheim LP, Puy JY, Lefebvre I, Dumontet C, Guitton J. Fully validated assay for the quantification of endogenous nucleoside mono- and triphosphates using online extraction coupled with liquid chromatography-tandem mass spectrometry. Anal Bioanal Chem. 2014;406:2925-41.

12. Lo Presti C, Fauvelle F, Jacob MC, Mondet J, Mossuz P. The metabolic reprogramming in acute myeloid leukemia patients depends on their genotype and is a prognostic marker. Blood Adv. 2021;5:156-66.

13. Li YC, Shih YH, Chen TC, et al. Redefining remission induction chemotherapy ineligibility by early mortality in de novo acute myeloid leukemia. J Clin Med. 2021;10:5768.

14. Schneider C, Oellerich T, Baldauf HM, et al. SAMHD1 is a biomarker for cytarabine response and a therapeutic target in acute myeloid leukemia. Nat Med. 2017;23:250-5.

15. Chen P, Aimiuwu J, Xie Z, et al. Biochemical modulation of aracytidine (Ara-C) effects by GTI-2040, a ribonucleotide reductase inhibitor, in K562 human leukemia cells. AAPS J. 2011;13:131-40.

16. Iwasaki H, Huang P, Keating MJ, Plunkett W. Differential incorporation of ara-C, gemcitabine, and fludarabine into replicating and repairing DNA in proliferating human leukemia cells. Blood. 1997;90:270-8.

17. Grem JL, Allegra CJ. Enhancement of the toxicity and DNA incorporation of arabinosyl-5-azacytosine and 1-beta-D-arabinofuranosylcytosine by cyclopentenyl cytosine. Cancer Res. 1990;50:7279-84.

18. Stockard B, Bhise N, Shin M, et al. Cellular metabolomics profiles associated with drug chemosensitivity in AML. Front Oncol. 2021;11:678008.

19. Liou JY, Lai HR, Hsu CH, et al. Modulation of human UMP/CMP kinase affects activation and cellular sensitivity of deoxycytidine analogs. Biochem Pharmacol. 2010;79:381-8.

20. Jeon SM. Regulation and function of AMPK in physiology and diseases. Exp Mol Med. 2016;48:e245.

21. Ji C, Yang B, Yang YL, et al. Exogenous cell-permeable C6 ceramide sensitizes multiple cancer cell lines to Doxorubicin-induced apoptosis by promoting AMPK activation and mTORC1 inhibition. Oncogene. 2010;29:6557-68.

22. Sujobert P, Poulain L, Paubelle E, et al. Co-activation of AMPK and mTORC1 induces cytotoxicity in acute myeloid leukemia. Cell Rep. 2015;11:1446-57.

23. Zhang X, Jia A, You J, et al. Purine metabolites regulate leukemic cell sensitivity toward cytarabine. Haematologica. 2025;110:1170-6.

24. van Gastel N, Spinelli JB, Sharda A, et al. Induction of a timed metabolic collapse to overcome cancer chemoresistance. Cell Metab. 2020;32:391-403.e6.